StockNews.com Begins Coverage on NeuroMetrix (NASDAQ:NURO)

Equities researchers at StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note issued on Tuesday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Stock Performance

NURO stock opened at $4.40 on Tuesday. NeuroMetrix has a 52 week low of $2.66 and a 52 week high of $4.73. The company has a market capitalization of $9.03 million, a PE ratio of -0.96 and a beta of 2.18. The company’s 50-day simple moving average is $4.20 and its 200 day simple moving average is $4.06.

Institutional Investors Weigh In On NeuroMetrix

An institutional investor recently bought a new position in NeuroMetrix stock. Renaissance Technologies LLC acquired a new position in shares of NeuroMetrix, Inc. (NASDAQ:NURO) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 11,560 shares of the medical device company’s stock, valued at approximately $46,000. Renaissance Technologies LLC owned 0.57% of NeuroMetrix at the end of the most recent reporting period. 19.40% of the stock is currently owned by hedge funds and other institutional investors.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.